MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
38.21
+0.53
+1.41%
Closed 19:11 12/31 EST
OPEN
37.75
PREV CLOSE
37.68
HIGH
38.93
LOW
37.54
VOLUME
947.12K
TURNOVER
0
52 WEEK HIGH
42.13
52 WEEK LOW
12.91
MARKET CAP
3.42B
P/E (TTM)
-35.2361
1D
5D
1M
3M
1Y
5Y
1D
Biotech Stocks Facing FDA Decision In January 2026
NASDAQ · 12/30/2025 08:21
Travere Therapeutics Chief Commercial Officer Peter Heerma Reports Sale of Common Shares
Reuters · 12/30/2025 02:12
Travere Therapeutics Chief Research Officer William E. Rote Reports Disposal of Common Shares
Reuters · 12/30/2025 02:06
Travere Therapeutics Chief Medical Officer Jula Inrig Reports Disposal of Common Shares
Reuters · 12/30/2025 02:02
Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin Reports Sale of Common Shares
Reuters · 12/30/2025 01:59
Weekly Report: what happened at TVTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:38
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday
NASDAQ · 12/24/2025 23:51
Cantor Fitzgerald sees Dimerix news as positive for Travere Therapeutics
TipRanks · 12/24/2025 17:00
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.